|Author: Jo Frowde. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer|
Uptravi is marketed by San Francisco-based Actelion Pharmaceuticals US, Inc.
Uptravi® (selexipag) is an oral IP prostacyclin receptor agonist marketed by Actelion Pharmaceuticals US, Inc., which was approved by the US FDA for the treatment of pulmonary arterial hypertension in December 2015. Common side effects include headache, diarrhea, jaw pain, nausea, muscle pain (myalgia), vomiting, pain in an extremity, and flushing. ISN.
Selexipag. About this treatment for pulmonary hypertension, including the GRIPHON clinical trial results, safety and tolerability, and dosing information. Actelion.
FDA Clears Uptravi® (Selexipag) for Pulmonary Arterial Hypertension. Uptravi® (selexipag) was shown to be effective in reducing hospitalization for pulmonary arterial hypertension (PAH) and reducing the risks of disease progression compared to placebo. FDA, 12/22/2015. (Also see: Pulmonary Hypertension Treatments)
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: